Bifunctional blockade: A novel immunotherapy approach for cervical cancer Editorial

  


Authors: Miller, K. M.; Friedman, C. F.
Title: Bifunctional blockade: A novel immunotherapy approach for cervical cancer
Abstract: SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so. See related article by Feng et al., p. 5297. ©2022 American Association for Cancer Research.
Keywords: neoplasm recurrence, local; transforming growth factor beta; immunology; immunotherapy; tumor recurrence; uterine cervical neoplasms; uterine cervix tumor; programmed death 1 ligand 1; antibodies, bispecific; bispecific antibody; humans; human; female; b7-h1 antigen; shr-1701
Journal Title: Clinical Cancer Research
Volume: 28
Issue: 24
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2022-12-15
Start Page: 5238
End Page: 5240
Language: English
DOI: 10.1158/1078-0432.Ccr-22-1779
PUBMED: 35947045
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144326291&doi=10.1158%2f1078-0432.CCR-22-1779&partnerID=40&md5=25dcd07eba5ca127c96ca6dfd0883fb3
Notes: Editorial -- Export Date: 3 January 2023 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Claire Frances Friedman
    117 Friedman
  2. Kathryn Miller
    21 Miller
Related MSK Work